You are here

Changes of Depression After First-year of Tofacitinib in RA Patients

Last updated on July 11, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients aged ≥18 years.

- Moderate to severe activity of rheumatoid arthritis (DAS28 ≥3.2).

- Patient for whom the physician decision has been made to initiate a treatment with
Tofacitinib.

- Patient with at least minimal level of depression (CUDOS questionnaire ≥11 points).

- Patient who have been prescribed Tofacitinib treatment according to SmPC and SUKL's
criteria for reimbursement.

- Evidence of a personally signed and dated informed consent document indicating that
the patient (or a legally acceptable representative) has been informed of all
pertinent aspects of the study is a requirement for inclusion into this study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Contraindications according to Xeljanz® SmPC

- Receipt of any investigational drug within 3 months before study inclusion.

- Patients who are investigational site staff members or patients who are Pfizer
employees directly involved in the conduct of the trial.

NCT03992781
Pfizer
Not yet recruiting
Changes of Depression After First-year of Tofacitinib in RA Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Systemic Lupus Erythematosus, Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Crohn Desease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
NCT02925338
All Genders
6+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now